Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combine... | NCT00413660 | Trialant
NCT00413660
Sponsor
Pfizer
Status
Completed
Last Update Posted
Jan 18, 2013Estimated
Enrollment
509Actual
Phase
Phase 2
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550
CP-690,550
CP-690,550
CP-690,550
CP-690,550
CP-690,550
placebo
Countries
United States
Argentina
Brazil
Bulgaria
Chile
Czechia
Hungary
Mexico
Poland
Slovakia
Spain
Sweden
Turkey (Türkiye)
Protocol Section
Identification Module
NCT ID
NCT00413660
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
A3921025
Secondary IDs
Not provided
Brief Title
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
Official Title
A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
Acronym
Not provided
Organization
PfizerINDUSTRY
Status Module
Record Verification Date
Jan 2013
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jan 2007
Primary Completion Date
Aug 2008Actual
Completion Date
Aug 2008Actual
First Submitted Date
Dec 18, 2006
First Submission Date that Met QC Criteria
Dec 18, 2006
First Posted Date
Dec 20, 2006Estimated
Results Waived
Not provided
Results First Submitted Date
Dec 4, 2012
Results First Submitted that Met QC Criteria
Dec 4, 2012
Results First Posted Date
Jan 8, 2013Estimated
Certification/Extension (aka Delayed Results) First Submitted Date
Apr 6, 2009
Certification/Extension First Submitted that Passed QC Review
Oct 7, 2009
Certification/Extension First Posted Date
Oct 12, 2009Estimated
Last Update Submitted Date
Jan 14, 2013
Last Update Posted Date
Jan 18, 2013Estimated
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
PfizerINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
Detailed Description
Not provided
Conditions Module
Conditions
Arthritis, Rheumatoid
Keywords
DMARD therapy
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
509Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
CP 690,550 1 mg BID
Experimental
Drug: CP-690,550
CP 690,550 10 mg BID
Experimental
Drug: CP-690,550
CP 690,550 15 mg
Experimental
Drug: CP-690,550
CP 690,550 3 mg BID
Experimental
Drug: CP-690,550
CP 690,550 5 mg BID
Experimental
Drug: CP-690,550
CP-690,550 20 mg QD
Experimental
Drug: CP-690,550
Placebo
Placebo Comparator
Dummy tablets
Other: placebo
Interventions
Name
Type
Description
Arm Group Labels
Other Names
CP-690,550
Drug
4 blinded tablets administered BID
CP 690,550 1 mg BID
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response: >= 20% improvement in tender joints count (TJC); >= 20% improvement in swollen joints count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Week 12
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: >= 20% improvement in TJC; >= 20% improvement in SJC; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Active rheumatoid arthritis
Inadequate response to stably dosed methotrexate
Exclusion Criteria:
Current therapy with any DMARD or biologic other than methotrexate
Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
See Also Links
Label
URL
To obtain contact information for a study center near you, click here.
CP-690,550 1 milligram (mg) tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 response: >= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: >= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.
Baseline up to Week 2, 4, 6, 8, 12
Tender Joints Count (TJC)
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Swollen Joints Count (SJC)
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Patient Global Assessment (PtGA) of Arthritis
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Physician Global Assessment of Arthritis
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
C-Reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (<=) 3.2 implied low disease activity and more than (>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (<) 2.6 = remission.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)
Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of >1.2 and a present score of <=3.2; none: an improvement of <=0.6 or >0.6 to <=1.2 with a present score of >5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
DAS28-3 (CRP) defined remission was classified as a score of <2.6.
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Baseline, Week 12, 24/ET
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Baseline, Week 12, 24/ET
Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Baseline, Week 12, 24/ET
Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Baseline, Week 12, 24/ET
Medical Outcome Study- Sleep Scale (MOS-SS)
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Baseline, Week 2, 12, 24/ET
Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range*100); total score range: 0 to 100; higher score = greater intensity of attribute.
Baseline, Week 2, 12, 24/ET
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Baseline, Week 2, 12, 24/ET
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET
FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.
Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17.
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
FG002
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
FG003
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
FG004
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
FG005
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
FG006
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
FG007
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
FG008
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
FG009
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
FG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
FG00071 subjects
FG00168 subjects
FG00271 subjects
FG00375 subjects
FG00475 subjects
FG00580 subjects
FG00669 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
Treated
FG00070 subjects
FG00168 subjects
FG00271 subjects
FG00374 subjects
FG00475 subjects
FG00580 subjects
FG00669 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
COMPLETED
FG00064 subjects
FG00161 subjects
FG00264 subjects
FG00367 subjects
FG00466 subjects
FG00570 subjects
FG00658 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
NOT COMPLETED
FG0007 subjects
FG0017 subjects
FG0027 subjects
FG0038 subjects
FG0049 subjects
FG00510 subjects
FG00611 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
Type
Comment
Reasons
Adverse Event
FG0001 subjects
FG0013 subjects
FG0021 subjects
FG0034 subjects
FG0046 subjects
FG0054 subjects
FG0061 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
Lack of Efficacy
FG0002 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0012 subjects
FG0020 subjects
FG0032 subjects
FG004
Randomized, Not Treated
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0031 subjects
FG004
Other
FG0003 subjects
FG0011 subjects
FG0026 subjects
FG0031 subjects
FG004
Post Week 12
Type
Comment
Milestone Data
STARTED
FG00043 subjects
FG00148 subjects
FG00264 subjects
FG00367 subjects
FG00466 subjects
FG00557 subjects
FG00640 subjects
FG00721 subjects
FG00813 subjects
FG00913 subjects
FG01018 subjects
COMPLETED
FG00040 subjects
FG00144 subjects
FG00256 subjects
FG00366 subjects
FG004
NOT COMPLETED
FG0003 subjects
FG0014 subjects
FG0028 subjects
FG0031 subjects
FG004
Type
Comment
Reasons
Adverse Event
FG0002 subjects
FG0010 subjects
FG0022 subjects
FG003
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
BG001
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
BG002
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
BG003
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
BG004
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
BG005
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
BG006
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
BG007
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00070
BG00168
BG00271
BG00374
BG00475
BG00580
BG00669
BG007507
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Customized
Number
participants
Title
Denominators
Categories
18 to 44 Years
Title
Measurements
BG00015
BG00123
BG00219
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00057
BG00152
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response: >= 20% improvement in tender joints count (TJC); >= 20% improvement in swollen joints count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Baseline Observation Carried Forward (BOCF).
Posted
Number
percentage of participants
Week 12
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG002
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG003
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG004
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG006
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
Units
Counts
Participants
OG00070
OG00168
OG00271
OG003
Title
Denominators
Categories
Title
Measurements
OG00047.14
OG00155.88
OG00256.34
OG003
Secondary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: >= 20% improvement in TJC; >= 20% improvement in SJC; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
Secondary
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 response: >= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.
Posted
Number
percentage of participants
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: >= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here "n" is number of participants evaluable at specific time points for each arm group, respectively.
Posted
Number
percentage of participants
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.
FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Last Observation Carried Forward (LOCF).
Posted
Mean
Standard Deviation
units on a scale
Baseline up to Week 2, 4, 6, 8, 12
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
Tender Joints Count (TJC)
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
tender joints
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
tender joints
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
Secondary
Swollen Joints Count (SJC)
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
swollen joints
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
swollen joints
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
Secondary
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
Patient Global Assessment (PtGA) of Arthritis
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Physician Global Assessment of Arthritis
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mm
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Secondary
C-Reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mg/dL
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
Secondary
Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
mg/dL
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
Secondary
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (<=) 3.2 implied low disease activity and more than (>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (<) 2.6 = remission.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)
Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of >1.2 and a present score of <=3.2; none: an improvement of <=0.6 or >0.6 to <=1.2 with a present score of >5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Number
percentage of participants
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
DAS28-3 (CRP) defined remission was classified as a score of <2.6.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Number
percentage of participants
Week 2, 4, 6, 8, 12, 16, 20, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
Secondary
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Secondary
Medical Outcome Study- Sleep Scale (MOS-SS)
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Secondary
Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range*100); total score range: 0 to 100; higher score = greater intensity of attribute.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
Secondary
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET
FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
FAS included all randomized participants who received at least 1 dose of study treatment. Here "N" (number of participants analyzed) signifies participants evaluable for this measure and "n" signifies participants evaluable at specific time points for each arm group, respectively.
Posted
Mean
Standard Deviation
units on a scale
Baseline, Week 2, 12, 24/ET
ID
Title
Description
OG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks.
OG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
Time Frame
Not provided
Description
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
CP-690,550 1 mg
CP-690,550 1 mg tablet orally twice daily up to Week 24.
1
49
28
49
EG001
CP-690,550 1 mg to CP-690,550 5 mg (R)
CP-690,550 1 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.
1
21
14
21
EG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily up to Week 24.
4
55
30
55
EG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
CP-690,550 3 mg tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.
0
13
10
13
EG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily up to Week 24.
4
71
40
71
EG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily up to Week 24.
1
74
45
74
EG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily up to Week 24.
6
75
46
75
EG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 24.
4
67
37
67
EG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose up to Week 12 followed by CP-690,550 5 mg tablet orally twice daily up to Week 24.
0
13
6
13
EG009
Placebo
Matching placebo tablet orally twice daily up to Week 24.
0
51
29
51
EG010
Placebo to CP-690,550 5 mg (R)
Matching placebo tablet orally twice daily up to Week 12 followed by CP-690,550 5 mg tablet orally twice up to Week 24.
0
18
12
18
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Atrial fibrillation
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG0030 affected13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
Cardiac failure
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Cardiac failure congestive
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Blindness
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Food poisoning
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Gastric ulcer
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Stomatitis
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Chest discomfort
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Chest pain
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pyrexia
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Ankle fracture
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Melanocytic naevus
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Migraine
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Dissociative disorder
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Uterine haemorrhage
Reproductive system and breast disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Respiratory failure
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Implantable defibrillator insertion
Surgical and medical procedures
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Circulatory collapse
Vascular disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG0030 affected13 at risk
EG0040 affected71 at risk
EG0052 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
Lymphadenitis
Blood and lymphatic system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Bradycardia
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Extrasystoles
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Palpitations
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Supraventricular extrasystoles
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Tinnitus
Ear and labyrinth disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Vertigo
Ear and labyrinth disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Cataract
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Conjunctivitis
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Vision blurred
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Visual disturbance
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Xerophthalmia
Eye disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Abdominal discomfort
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0011 affected21 at risk
EG0022 affected55 at risk
EG003
Abdominal tenderness
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Breath odour
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0007 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Flatulence
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0012 affected21 at risk
EG0022 affected55 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0011 affected21 at risk
EG0023 affected55 at risk
EG003
Rectal haemorrhage
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Stomach discomfort
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0022 affected55 at risk
EG003
Chest discomfort
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Chest pain
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0022 affected55 at risk
EG003
Fatigue
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Irritability
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Mucosal inflammation
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Oedema peripheral
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pyrexia
General disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Allergy to arthropod bite
Immune system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Bronchitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0022 affected55 at risk
EG003
Ear infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Erysipelas
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Gastroenteritis viral
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Herpes simplex
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Herpes zoster
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Influenza
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Laryngitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0012 affected21 at risk
EG0022 affected55 at risk
EG003
Onychomycosis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Oral fungal infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Oral herpes
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0012 affected21 at risk
EG0021 affected55 at risk
EG003
Parainfluenzae virus infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Pharyngitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0023 affected55 at risk
EG003
Pharyngitis streptococcal
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pharyngotonsillitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Pulpitis dental
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rhinitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Sinusitis bacterial
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tinea cruris
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tinea pedis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tonsillitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tracheitis
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0022 affected55 at risk
EG003
Viral infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Vulvovaginal mycotic infection
Infections and infestations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Animal bite
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Excoriation
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Fall
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Fibula fracture
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Foot fracture
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Injury
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Joint sprain
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Muscle strain
Injury, poisoning and procedural complications
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Blood cholesterol increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Electrocardiogram ST-T change
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Electrocardiogram T wave abnormal
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Electrocardiogram abnormal
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Haematocrit decreased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Haemoglobin decreased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Hepatic enzyme increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Transaminases increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Weight decreased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Weight increased
Investigations
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Anorexia
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Glucose tolerance impaired
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Hypercholesterolaemia
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Hyperlipidaemia
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Hypertriglyceridaemia
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Hyperuricaemia
Metabolism and nutrition disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Bone pain
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Fibromyalgia
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Osteochondrosis
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Osteopenia
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rheumatoid arthritis
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Synovial cyst
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Burning sensation
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Cluster headache
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Dizziness
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Headache
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Hypersomnia
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Sciatica
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Sinus headache
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Somnolence
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Tension headache
Nervous system disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Emotional disorder
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0021 affected55 at risk
EG003
Nervousness
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Nightmare
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Sleep disorder
Psychiatric disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Leukocyturia
Renal and urinary disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Nephrolithiasis
Renal and urinary disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Pyuria
Renal and urinary disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Genital discharge
Reproductive system and breast disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Ovarian cyst
Reproductive system and breast disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Allergic sinusitis
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Asthma
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0022 affected55 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Nasal congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Nasal mucosal disorder
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Pharyngeal inflammation
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Pharyngolaryngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Pulmonary congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Respiratory disorder
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rhinitis allergic
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rhinorrhoea
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Sinus congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Wheezing
Respiratory, thoracic and mediastinal disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Acne
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Alopecia
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Angioedema
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Dermatitis
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0021 affected55 at risk
EG003
Ecchymosis
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Eczema
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Erythema
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Intertrigo
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Palpable purpura
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0011 affected21 at risk
EG0020 affected55 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0022 affected55 at risk
EG003
Rash generalised
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Rash papular
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Urticaria
Skin and subcutaneous tissue disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Hot flush
Vascular disorders
MedDRA 11.0
Non-systematic Assessment
EG0001 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Hypertension
Vascular disorders
MedDRA 11.0
Non-systematic Assessment
EG0002 affected49 at risk
EG0011 affected21 at risk
EG0022 affected55 at risk
EG003
Venous stasis
Vascular disorders
MedDRA 11.0
Non-systematic Assessment
EG0000 affected49 at risk
EG0010 affected21 at risk
EG0020 affected55 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Point of Contact
Title
Organization
Phone
Extension
Email
Pfizer ClinicalTrials.gov Call Center
Pfizer, Inc.
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
ID
Term
D001172
Arthritis, Rheumatoid
Ancestor Terms
ID
Term
D001168
Arthritis
D007592
Joint Diseases
D009140
Musculoskeletal Diseases
D012216
Rheumatic Diseases
D003240
Connective Tissue Diseases
D017437
Skin and Connective Tissue Diseases
D001327
Autoimmune Diseases
D007154
Immune System Diseases
Browse Leaves
Not provided
Browse Branches
Not provided
ID
Term
C479163
tofacitinib
Ancestor Terms
Not provided
Browse Leaves
Not provided
Browse Branches
Not provided
0 subjects
FG0050 subjects
FG0065 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
1 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
0 subjects
FG0052 subjects
FG0062 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
2 subjects
FG0054 subjects
FG0063 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
60 subjects
FG00554 subjects
FG00637 subjects
FG00721 subjects
FG00813 subjects
FG00912 subjects
FG01017 subjects
6 subjects
FG0053 subjects
FG0063 subjects
FG0070 subjects
FG0080 subjects
FG0091 subjects
FG0101 subjects
1 subjects
FG0044 subjects
FG0052 subjects
FG0062 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
Lack of Efficacy
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0091 subjects
FG0100 subjects
Lost to Follow-up
FG0000 subjects
FG0011 subjects
FG0021 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
Withdrawal by Subject
FG0000 subjects
FG0011 subjects
FG0021 subjects
FG0030 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0101 subjects
Other
FG0001 subjects
FG0012 subjects
FG0023 subjects
FG0030 subjects
FG0041 subjects
FG0051 subjects
FG0061 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
9
BG00414
BG00515
BG00617
BG007112
45 to 64 Years
Title
Measurements
BG00047
BG00131
BG00242
BG00349
BG00449
BG00549
BG00640
BG007307
Greater Than or Equal to (>=) 65 Years
Title
Measurements
BG0008
BG00114
BG00210
BG00316
BG00412
BG00516
BG00612
BG00788
57
BG00355
BG00466
BG00563
BG00656
BG007406
Male
BG00013
BG00116
BG00214
BG00319
BG0049
BG00517
BG00613
BG007101
74
OG00475
OG00580
OG00669
58.11
OG00456.00
OG00556.25
OG00636.23
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00813
OG00969
OG01018
Title
Denominators
Categories
Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00021.43
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00236.76
OG003NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00430.99
OG00531.08
OG00640.00
OG00733.75
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00915.94
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00037.14
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00245.59
OG003
Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00044.29
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00254.41
OG003
Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00050.00
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00254.41
OG003
Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00063.3
OG0010.0
OG00260.0
OG003
Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00059.2
OG0010.0
OG00267.3
OG003
Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00059.2
OG0010.0
OG00265.5
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00813
OG00969
OG01018
Title
Denominators
Categories
Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0001.43
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.88
OG003NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0045.63
OG0054.05
OG00617.33
OG00715.00
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.90
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0004.29
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00216.18
OG003
Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00010.00
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00229.41
OG003
Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00017.14
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00232.35
OG003
Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00022.86
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00229.41
OG003
Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00038.8
OG0010.0
OG00243.6
OG003
Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00038.8
OG0010.0
OG00245.5
OG003
Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00044.9
OG0010.0
OG00234.5
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00813
OG00969
OG01018
Title
Denominators
Categories
Week 2 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0001.43
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0021.47
OG003NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.41
OG0051.35
OG0066.67
OG0072.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.00
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0002.86
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0027.35
OG003
Week 6 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0001.43
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00213.24
OG003
Week 8 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0008.57
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00214.71
OG003
Week 12 (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0004.29
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00220.59
OG003
Week 16 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00016.3
OG0010.0
OG00221.8
OG003
Week 20 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00020.4
OG0010.0
OG00229.1
OG003
Week 24 (n=49,21,55,13,71,74,75,67,13,51,18)
Title
Measurements
OG00028.6
OG0010.0
OG00223.6
OG003
OG002
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG003
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG004
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG006
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
Units
Counts
Participants
OG00070
OG00168
OG00271
OG00374
OG00475
OG00580
OG00669
Title
Denominators
Categories
Week 2
Title
Measurements
OG000-14.07± 247.36
OG00122.16± 243.19
OG0024.47± 319.92
OG003-21.34± 661.05
OG00488.72± 287.91
OG00536.55± 267.26
OG006-113.31± 429.17
Week 4
Title
Measurements
OG00061.66± 622.43
OG001163.40± 659.05
OG00292.24± 919.49
OG003
Week 6
Title
Measurements
OG000244.11± 948.25
OG001442.29± 1087.57
OG002348.96± 1446.07
OG003
Week 8
Title
Measurements
OG000464.42± 1424.59
OG001772.65± 1594.84
OG002693.90± 1952.07
OG003
Week 12
Title
Measurements
OG000995.34± 2349.99
OG0011511.40± 2711.76
OG0021420.20± 3284.51
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00023.64± 11.60
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00222.79± 10.57
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00421.46± 12.95
OG00524.84± 12.51
OG00623.68± 12.71
OG00723.11± 12.67
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00921.59± 13.18
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00018.62± 12.09
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00217.71± 11.87
OG003
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG00015.01± 11.19
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00212.80± 10.36
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG00014.48± 12.18
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00211.12± 9.56
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG00014.24± 12.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00210.18± 10.30
OG003
Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)
Title
Measurements
OG00012.84± 12.79
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0028.83± 9.61
OG003
Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)
Title
Measurements
OG0008.07± 9.11
OG00119.33± 15.70
OG0026.02± 7.97
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG0008.08± 11.06
OG00113.76± 12.02
OG0025.32± 6.35
OG003
Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG0007.45± 10.88
OG00114.80± 14.09
OG0025.52± 5.65
OG003
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00268
OG00313
OG00468
OG00573
OG00673
OG00779
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-4.68± 7.26
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-5.09± 9.91
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-6.06± 9.36
OG005-7.62± 8.48
OG006-7.68± 10.20
OG007-7.78± 9.67
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.27± 7.50
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG000-8.28± 8.68
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-10.26± 9.63
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG000-8.86± 10.26
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-11.78± 10.82
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG000-9.08± 10.79
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-12.69± 11.57
OG003
Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)
Title
Measurements
OG000-10.67± 10.73
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-14.00± 12.56
OG003
Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)
Title
Measurements
OG000-14.05± 9.97
OG001-6.81± 7.90
OG002-17.44± 10.54
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG000-13.64± 10.63
OG001-12.38± 10.61
OG002-18.36± 9.52
OG003
Week 24 (n=40,21,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG000-14.53± 10.83
OG001-10.40± 11.27
OG002-18.16± 9.82
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00016.51± 8.24
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00215.68± 8.56
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00414.06± 7.44
OG00514.74± 7.46
OG00615.33± 7.02
OG00715.21± 8.04
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00915.72± 8.83
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00012.62± 7.81
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00210.97± 9.02
OG003
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG0009.85± 7.74
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0028.58± 8.20
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG0008.77± 6.34
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0027.23± 7.28
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG0008.20± 7.84
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0026.63± 7.63
OG003
Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)
Title
Measurements
OG0008.31± 8.41
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.36± 6.64
OG003
Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)
Title
Measurements
OG0005.83± 7.43
OG0018.90± 7.55
OG0023.49± 3.78
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG0004.95± 7.82
OG0017.33± 8.75
OG0023.36± 5.19
OG003
Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG0004.10± 4.83
OG0018.65± 8.77
OG0023.73± 5.35
OG003
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00268
OG00313
OG00468
OG00573
OG00673
OG00779
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-3.43± 5.98
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-4.71± 7.40
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-4.24± 6.33
OG005-4.75± 5.57
OG006-5.45± 7.74
OG007-5.04± 7.45
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.12± 5.00
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG000-6.19± 6.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-7.25± 8.80
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG000-7.41± 6.58
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-8.42± 9.28
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG000-7.80± 8.13
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-9.03± 9.79
OG003
Week 12 (n=64,0,59,0,64,66,66,70,0,61,0)
Title
Measurements
OG000-7.61± 9.15
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-10.47± 9.71
OG003
Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)
Title
Measurements
OG000-10.67± 8.78
OG001-5.95± 6.99
OG002-13.00± 8.90
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG000-10.95± 8.32
OG001-7.52± 8.20
OG002-13.36± 8.25
OG003
Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG000-12.15± 7.83
OG001-6.60± 7.50
OG002-13.00± 8.52
OG003
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00267
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,66,0,71,74,75,80,0,69,0)
Title
Measurements
OG00059.96± 25.67
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00255.05± 24.81
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00454.87± 26.68
OG00556.66± 25.42
OG00655.83± 22.85
OG00759.61± 23.61
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00951.19± 27.72
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,67,0,68,73,73,79,0,66,0)
Title
Measurements
OG00049.53± 24.99
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00243.33± 23.26
OG003
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG00045.57± 24.99
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00237.83± 22.77
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)
Title
Measurements
OG00038.74± 24.31
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00233.75± 25.06
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG00038.97± 23.33
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00228.81± 23.86
OG003
Week 12 (n=64,0,59,0,64,65,66,70,0,61,0)
Title
Measurements
OG00035.92± 22.49
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00230.90± 24.44
OG003
Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)
Title
Measurements
OG00027.83± 18.65
OG00140.38± 21.81
OG00229.67± 24.13
OG003
Week 20 (n=39,21,43,13,57,65,59,55,12,37,17)
Title
Measurements
OG00029.28± 22.75
OG00135.71± 22.42
OG00226.63± 23.48
OG003
Week 24 (n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG00025.53± 21.05
OG00138.15± 26.27
OG00225.98± 20.61
OG003
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00265
OG00313
OG00468
OG00573
OG00673
OG00779
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=65,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-9.49± 24.31
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-11.00± 20.82
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-10.76± 26.22
OG005-15.30± 25.46
OG006-17.67± 24.58
OG007-18.84± 25.59
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-4.55± 25.28
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,63,0,67,70,72,76,0,66,0)
Title
Measurements
OG000-13.44± 26.39
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-17.11± 23.98
OG003
Week 6 (n=66,0,63,0,69,71,72,74,0,61,0)
Title
Measurements
OG000-19.56± 31.29
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-22.71± 28.84
OG003
Week 8 (n=66,0,60,0,66,67,70,73,0,61,0)
Title
Measurements
OG000-19.91± 26.68
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-26.23± 29.28
OG003
Week 12 (n=64,0,57,0,64,65,66,70,0,61,0)
Title
Measurements
OG000-23.16± 28.49
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-24.39± 30.89
OG003
Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)
Title
Measurements
OG000-34.02± 31.75
OG001-13.48± 25.66
OG002-27.19± 24.93
OG003
Week 20 (n=39,21,41,13,57,65,59,55,12,37,17)
Title
Measurements
OG000-31.54± 36.96
OG001-18.14± 25.06
OG002-32.37± 26.83
OG003
Week 24 (n=40,20,42,13,55,63,60,53,12,36,17)
Title
Measurements
OG000-36.08± 32.62
OG001-15.40± 24.78
OG002-33.19± 25.68
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00779
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,79,0,69,0)
Title
Measurements
OG00062.47± 24.77
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00258.91± 22.94
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00454.62± 23.71
OG00558.35± 23.14
OG00656.09± 21.42
OG00757.24± 25.64
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00951.88± 26.44
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00053.19± 22.93
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00241.96± 23.12
OG003
Week 4 (n=68,0,65,0,67,70,72,76,0,66,0)
Title
Measurements
OG00047.87± 23.21
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00239.78± 22.47
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,61,0)
Title
Measurements
OG00042.30± 22.34
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00236.08± 23.56
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG00041.06± 21.76
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00230.11± 22.38
OG003
Week 12 (n=64,0,59,0,64,65,66,70,0,60,0)
Title
Measurements
OG00038.78± 22.91
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00234.42± 25.15
OG003
Week 16 (n=42,21,45,13,58,66,61,54,12,37,16)
Title
Measurements
OG00030.76± 20.40
OG00138.29± 19.76
OG00229.84± 24.12
OG003
Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)
Title
Measurements
OG00029.85± 22.86
OG00137.95± 23.62
OG00228.16± 22.36
OG003
Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00028.23± 21.42
OG00138.55± 27.08
OG00225.93± 22.22
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00268
OG00313
OG00468
OG00573
OG00673
OG00778
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)
Title
Measurements
OG000-8.57± 26.12
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-16.96± 20.11
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-12.37± 21.83
OG005-16.74± 24.15
OG006-20.25± 26.92
OG007-15.38± 30.86
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-5.82± 24.96
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)
Title
Measurements
OG000-13.90± 25.53
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-19.40± 25.40
OG003
Week 6 (n=66,0,65,0,69,71,72,73,0,61,0)
Title
Measurements
OG000-18.71± 29.02
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-22.02± 25.83
OG003
Week 8 (n=66,0,62,0,66,67,70,72,0,61,0)
Title
Measurements
OG000-20.35± 27.84
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-27.48± 26.13
OG003
Week 12 (n=64,0,59,0,64,65,66,69,0,60,0)
Title
Measurements
OG000-22.78± 28.81
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-23.95± 29.82
OG003
Week 16 (n=42,21,45,13,58,66,61,53,12,37,16)
Title
Measurements
OG000-33.60± 31.45
OG001-15.86± 22.28
OG002-28.00± 28.15
OG003
Week 20 (n=39,21,43,13,57,66,59,54,12,36,17)
Title
Measurements
OG000-34.56± 31.99
OG001-16.19± 24.18
OG002-30.93± 25.67
OG003
Week 24 (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG000-36.68± 29.89
OG001-15.30± 32.99
OG002-32.11± 25.76
OG003
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00062.66± 16.00
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00257.50± 18.47
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00456.51± 19.00
OG00560.77± 16.75
OG00660.51± 14.26
OG00758.75± 17.90
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00958.30± 15.25
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00049.49± 21.64
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00241.07± 19.88
OG003
Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)
Title
Measurements
OG00041.69± 21.31
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00236.92± 21.20
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG00037.38± 17.11
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00231.51± 21.25
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG00035.71± 21.03
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00226.60± 20.34
OG003
Week 12 (n=63,0,59,0,64,66,65,70,0,61,0)
Title
Measurements
OG00033.65± 20.06
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00226.17± 21.33
OG003
Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)
Title
Measurements
OG00023.95± 16.25
OG00144.19± 24.68
OG00219.77± 19.74
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG00020.44± 18.10
OG00134.29± 16.64
OG00220.91± 18.21
OG003
Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)
Title
Measurements
OG00018.90± 16.51
OG00136.53± 21.17
OG00220.26± 18.12
OG003
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00067
OG00121
OG00268
OG00313
OG00468
OG00573
OG00673
OG00779
OG00812
OG00968
OG01017
Title
Denominators
Categories
Week 2 (n=67,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-12.88± 17.84
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-16.43± 19.20
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-14.60± 24.01
OG005-17.88± 17.66
OG006-24.30± 18.32
OG007-16.61± 19.17
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-8.82± 13.20
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)
Title
Measurements
OG000-20.66± 19.47
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-20.80± 22.47
OG003
Week 6 (n=66,0,65,0,69,71,72,74,0,62,0)
Title
Measurements
OG000-25.02± 20.89
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-26.34± 24.05
OG003
Week 8 (n=66,0,62,0,66,67,70,73,0,61,0)
Title
Measurements
OG000-26.50± 22.83
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-30.92± 22.85
OG003
Week 12 (n=63,0,59,0,64,66,66,70,0,61,0)
Title
Measurements
OG000-28.76± 23.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-31.69± 24.30
OG003
Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)
Title
Measurements
OG000-39.33± 19.85
OG001-16.95± 26.42
OG002-39.23± 23.11
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG000-42.21± 23.73
OG001-26.86± 23.81
OG002-38.70± 20.41
OG003
Week 24 (n=40,19,43,13,55,64,60,53,11,36,17)
Title
Measurements
OG000-44.15± 22.39
OG001-24.11± 24.91
OG002-39.98± 21.13
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00266
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,66,0,71,74,75,80,0,69,0)
Title
Measurements
OG0001.58± 0.57
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0021.36± 0.75
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.44± 0.64
OG0051.33± 0.60
OG0061.41± 0.64
OG0071.46± 0.58
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.20± 0.73
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG0001.41± 0.61
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0021.14± 0.75
OG003
Week 4 (n=68,0,65,0,67,70,72,75,0,66,0)
Title
Measurements
OG0001.32± 0.61
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0021.03± 0.69
OG003
Week 6 (n=66,0,64,0,69,71,72,74,0,61,0)
Title
Measurements
OG0001.23± 0.57
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.96± 0.69
OG003
Week 8 (n=66,0,62,0,66,67,70,71,0,61,0)
Title
Measurements
OG0001.22± 0.59
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.93± 0.68
OG003
Week 12 (n=64,0,59,0,64,65,66,68,0,61,0)
Title
Measurements
OG0001.19± 0.63
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.92± 0.75
OG003
Week 16 (n=42,21,45,13,58,66,61,55,12,37,16)
Title
Measurements
OG0001.05± 0.59
OG0011.42± 0.64
OG0020.82± 0.72
OG003
Week 20 (n=39,21,44,13,57,66,59,55,12,37,17)
Title
Measurements
OG0000.95± 0.58
OG0011.33± 0.72
OG0020.77± 0.68
OG003
Week 24 (n=40,20,44,13,54,63,59,53,12,36,17)
Title
Measurements
OG0000.99± 0.57
OG0011.38± 0.74
OG0020.85± 0.68
OG003
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00266
OG00313
OG00468
OG00573
OG00673
OG00779
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-0.15± 0.38
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.23± 0.49
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.23± 0.41
OG005-0.18± 0.42
OG006-0.24± 0.40
OG007-0.23± 0.45
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.05± 0.36
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=68,0,63,0,67,70,72,75,0,66,0)
Title
Measurements
OG000-0.24± 0.46
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.36± 0.52
OG003
Week 6 (n=66,0,62,0,69,71,72,74,0,61,0)
Title
Measurements
OG000-0.31± 0.45
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.39± 0.53
OG003
Week 8 (n=66,0,61,0,66,67,70,71,0,61,0)
Title
Measurements
OG000-0.34± 0.48
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.41± 0.63
OG003
Week 12 (n=64,0,58,0,64,65,66,68,0,61,0)
Title
Measurements
OG000-0.37± 0.48
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.48± 0.61
OG003
Week 16 (n=42,21,44,13,58,66,61,55,12,37,16)
Title
Measurements
OG000-0.52± 0.48
OG001-0.16± 0.50
OG002-0.59± 0.64
OG003
Week 20 (n=39,21,43,13,57,66,59,55,12,37,17)
Title
Measurements
OG000-0.62± 0.47
OG001-0.24± 0.42
OG002-0.62± 0.68
OG003
Week 24 (n=40,20,42,13,54,63,59,53,12,36,17)
Title
Measurements
OG000-0.60± 0.52
OG001-0.21± 0.58
OG002-0.53± 0.65
OG003
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00016.30± 18.08
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00215.85± 19.34
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00418.03± 24.96
OG00514.42± 17.81
OG00617.21± 16.94
OG00714.68± 17.19
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00918.88± 19.55
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG00014.54± 19.53
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0028.20± 11.77
OG003
Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG00010.28± 11.83
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00210.11± 15.29
OG003
Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG00010.55± 9.79
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0028.34± 13.70
OG003
Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG0009.62± 11.78
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0027.64± 11.54
OG003
Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)
Title
Measurements
OG0008.53± 9.59
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0029.54± 13.52
OG003
Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG0007.80± 10.30
OG0017.02± 8.51
OG00210.72± 18.93
OG003
Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)
Title
Measurements
OG0008.96± 11.64
OG0018.55± 12.87
OG0027.71± 10.88
OG003
Week 24 (n=39,20,43,13,53,63,56,52,12,36,17)
Title
Measurements
OG0007.63± 10.26
OG0016.02± 7.31
OG00210.31± 17.43
OG003
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00065
OG00121
OG00263
OG00313
OG00463
OG00569
OG00668
OG00774
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 2 (n=65,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG000-2.05± 18.32
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-6.93± 14.85
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-11.38± 19.27
OG005-9.19± 19.90
OG006-11.87± 15.22
OG007-6.56± 12.70
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.64± 14.26
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG000-6.07± 14.44
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-5.12± 17.24
OG003
Week 6 (n=64,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG000-5.92± 16.61
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-6.97± 17.77
OG003
Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG000-5.94± 16.03
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-7.42± 14.21
OG003
Week 12 (n=61,0,57,0,60,63,62,65,0,60,0)
Title
Measurements
OG000-7.56± 17.07
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-6.28± 14.07
OG003
Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG000-6.96± 10.61
OG001-11.26± 21.64
OG002-7.04± 21.18
OG003
Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)
Title
Measurements
OG000-6.21± 10.94
OG001-9.73± 22.12
OG002-11.31± 16.46
OG003
Week 24 (n=39,20,43,43,53,63,56,52,12,36,17)
Title
Measurements
OG000-7.61± 11.78
OG001-8.07± 10.28
OG002-7.57± 22.26
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,79,0,69,0)
Title
Measurements
OG0005.48± 0.80
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.31± 0.95
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0045.14± 0.84
OG0055.28± 0.85
OG0065.39± 0.89
OG0075.34± 0.87
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0095.26± 0.96
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=64,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG0004.88± 1.04
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.46± 1.03
OG003
Week 4 (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG0004.45± 1.08
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.03± 1.17
OG003
Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG0004.32± 1.12
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.74± 1.30
OG003
Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG0004.21± 1.22
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.63± 1.27
OG003
Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)
Title
Measurements
OG0003.98± 1.15
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.46± 1.38
OG003
Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG0003.59± 1.15
OG0014.33± 1.16
OG0023.11± 1.23
OG003
Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)
Title
Measurements
OG0003.48± 1.28
OG0013.83± 1.62
OG0023.06± 1.25
OG003
Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)
Title
Measurements
OG0003.39± 1.15
OG0013.88± 1.49
OG0023.14± 1.26
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00064
OG00121
OG00263
OG00313
OG00463
OG00569
OG00668
OG00773
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 2 (n=64,0,63,0,63,69,68,73,0,61,0)
Title
Measurements
OG000-0.55± 0.76
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.78± 0.92
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.86± 0.82
OG005-1.07± 0.84
OG006-1.22± 1.08
OG007-1.01± 0.97
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.26± 0.78
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=65,0,61,0,62,64,65,69,0,61,0)
Title
Measurements
OG000-0.99± 0.91
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-1.23± 1.19
OG003
Week 6 (n=63,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG000-1.13± 1.03
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-1.52± 1.27
OG003
Week 8 (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG000-1.22± 1.14
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-1.61± 1.18
OG003
Week 12 (n=61,0,55,0,60,63,62,65,0,60,0)
Title
Measurements
OG000-1.45± 1.13
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-1.85± 1.27
OG003
Week 16 (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG000-1.87± 1.13
OG001-1.14± 0.99
OG002-2.27± 1.14
OG003
Week 20 (n=39,21,44,13,57,63,57,55,12,36,17)
Title
Measurements
OG000-1.94± 1.26
OG001-1.64± 1.25
OG002-2.41± 1.26
OG003
Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)
Title
Measurements
OG000-2.06± 1.22
OG001-1.55± 1.07
OG002-2.29± 1.19
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00064
OG00121
OG00263
OG00313
OG00463
OG00569
OG00668
OG00774
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG0004.7
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.8
OG003NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0049.5
OG00513.0
OG00616.2
OG00712.2
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.3
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG00023.4
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00244.4
OG003
Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0)
Title
Measurements
OG00071.9
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00250.8
OG003
Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG00010.8
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00221.3
OG003
Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG00041.5
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00245.9
OG003
Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0)
Title
Measurements
OG00047.7
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00232.8
OG003
Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG00011.1
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00229.5
OG003
Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG00050.8
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00242.6
OG003
Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0)
Title
Measurements
OG00038.1
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00227.9
OG003
Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG00019.0
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00230.5
OG003
Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG00046.0
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00247.5
OG003
Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0)
Title
Measurements
OG00034.9
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00222.0
OG003
Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0)
Title
Measurements
OG00023.0
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00245.5
OG003
Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0)
Title
Measurements
OG00049.2
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00232.7
OG003
Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0)
Title
Measurements
OG00027.9
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00221.8
OG003
Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG00040.5
OG00119.0
OG00255.8
OG003
Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG00050.0
OG00138.1
OG00232.6
OG003
Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16)
Title
Measurements
OG0009.5
OG00142.9
OG00211.6
OG003
Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00064
OG00121
OG00263
OG00313
OG00463
OG00568
OG00668
OG00774
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 2 (n=64,0,63,0,63,68,68,74,0,61,0)
Title
Measurements
OG0001.56
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.17
OG003NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.59
OG0054.41
OG00613.24
OG0074.05
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.28
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 4 (n=65,0,61,0,62,63,65,70,0,61,0)
Title
Measurements
OG0004.62
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00214.75
OG003
Week 6 (n=63,0,61,0,66,66,66,69,0,58,0)
Title
Measurements
OG0003.17
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00219.67
OG003
Week 8 (n=63,0,59,0,62,61,67,67,0,58,0)
Title
Measurements
OG0007.94
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00222.03
OG003
Week 12 (n=61,0,55,0,60,62,62,65,0,60,0)
Title
Measurements
OG0006.56
OG001NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00230.91
OG003
Week 16 (n=42,21,43,13,54,63,58,55,9,37,16)
Title
Measurements
OG00014.3
OG0019.5
OG00241.9
OG003
Week 20 (n=39,21,44,13,57,62,57,55,12,36,17)
Title
Measurements
OG00020.5
OG00128.6
OG00243.2
OG003
Week 24 (n=39,20,42,13,53,63,56,52,12,36,17)
Title
Measurements
OG00023.1
OG00125.0
OG00235.7
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00120
OG00268
OG00313
OG00471
OG00573
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00031.48± 10.33
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00233.20± 11.04
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00431.93± 9.66
OG00531.92± 9.15
OG00631.50± 9.29
OG00730.23± 9.70
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.01± 11.06
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00034.53± 8.52
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00234.45± 10.52
OG003
Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00034.14± 6.60
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00234.60± 8.35
OG003
Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00035.08± 6.77
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.17± 8.02
OG003
Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00040.32± 9.95
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00242.36± 10.07
OG003
Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00037.76± 10.41
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00238.88± 11.35
OG003
Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00034.72± 11.55
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.18± 14.16
OG003
Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00038.98± 11.58
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00240.07± 11.65
OG003
Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00033.13± 6.72
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00233.73± 8.33
OG003
Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0)
Title
Measurements
OG00040.39± 11.42
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00241.47± 12.68
OG003
Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00035.05± 10.73
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00236.49± 11.63
OG003
Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00038.47± 8.77
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00239.25± 10.85
OG003
Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00041.62± 8.02
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00242.76± 11.30
OG003
Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00037.85± 8.10
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00239.04± 8.74
OG003
Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00045.45± 9.82
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00246.80± 10.08
OG003
Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00041.18± 11.32
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00243.54± 11.20
OG003
Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00039.47± 12.12
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00239.14± 12.47
OG003
Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00043.84± 10.95
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00244.57± 10.95
OG003
Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00037.24± 8.19
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00238.70± 9.73
OG003
Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG00044.86± 11.45
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00043.62± 10.40
OG00139.40± 10.26
OG00242.84± 12.53
OG003
Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00040.23± 11.08
OG00134.30± 10.59
OG00240.59± 13.86
OG003
Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00045.92± 11.10
OG00138.74± 10.58
OG00245.66± 12.59
OG003
Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00039.94± 8.41
OG00136.79± 9.76
OG00240.31± 9.95
OG003
Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG00046.62± 12.04
OG00139.10± 11.18
OG00246.21± 13.26
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00063
OG00120
OG00259
OG00313
OG00464
OG00564
OG00665
OG00770
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0003.98± 7.08
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.39± 9.60
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.57± 8.25
OG0054.18± 11.13
OG0065.96± 8.21
OG0077.40± 9.15
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.24± 8.79
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0003.77± 8.00
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.61± 11.45
OG003
Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0007.29± 8.12
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0028.80± 11.96
OG003
Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0002.94± 7.04
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.84± 7.61
OG003
Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0005.10± 8.99
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.29± 9.92
OG003
Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0003.72± 10.54
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.99± 10.54
OG003
Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0004.26± 10.65
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0023.69± 13.12
OG003
Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0004.92± 9.27
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0024.63± 10.01
OG003
Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0004.27± 6.38
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.16± 8.82
OG003
Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0)
Title
Measurements
OG0004.30± 9.47
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG0005.86± 9.36
OG0013.27± 12.31
OG0024.09± 11.10
OG003
Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG0004.28± 11.30
OG0012.33± 12.82
OG0025.48± 16.05
OG003
Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG0007.25± 12.82
OG0011.83± 8.73
OG0024.99± 11.52
OG003
Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG0007.47± 7.90
OG0012.91± 7.31
OG0026.78± 7.17
OG003
Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17)
Title
Measurements
OG0005.48± 12.35
OG0011.93± 11.99
OG0024.31± 13.10
OG003
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0000.45± 0.29
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.46± 0.33
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.50± 0.30
OG0050.48± 0.28
OG0060.46± 0.31
OG0070.49± 0.28
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.49± 0.33
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)
Title
Measurements
OG0000.63± 0.20
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.59± 0.30
OG003
Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)
Title
Measurements
OG0000.66± 0.23
OG0010.46± 0.42
OG0020.67± 0.26
OG003
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00063
OG00120
OG00259
OG00313
OG00464
OG00565
OG00664
OG00770
OG00812
OG00961
OG01017
Title
Denominators
Categories
Week 12 (n=63,0,59,0,64,65,64,70,0,61,0)
Title
Measurements
OG0000.15± 0.26
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.16± 0.37
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.11± 0.32
OG0050.17± 0.27
OG0060.18± 0.29
OG0070.16± 0.29
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.05± 0.35
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 24 (n=40,20,44,13,55,63,60,52,12,36,17)
Title
Measurements
OG0000.20± 0.30
OG0010.00± 0.30
OG0020.23± 0.33
OG003
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00574
OG00675
OG00780
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0)
Title
Measurements
OG00040.62± 18.87
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00244.46± 21.58
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00438.12± 18.93
OG00536.94± 18.49
OG00640.90± 22.41
OG00738.46± 21.21
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00938.26± 19.58
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0)
Title
Measurements
OG00041.94± 18.04
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00245.65± 20.86
OG003
Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0)
Title
Measurements
OG00048.14± 25.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00243.82± 26.99
OG003
Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00020.00± 24.55
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00222.94± 24.50
OG003
Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG00044.43± 23.13
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00249.10± 27.47
OG003
Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0)
Title
Measurements
OG0000.51± 0.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.44± 0.50
OG003
Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0)
Title
Measurements
OG0006.87± 1.73
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0026.72± 1.60
OG003
Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0)
Title
Measurements
OG00031.59± 30.76
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.29± 32.07
OG003
Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0)
Title
Measurements
OG00035.14± 20.30
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00238.63± 23.51
OG003
Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0)
Title
Measurements
OG00039.65± 21.00
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00237.89± 22.17
OG003
Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00039.04± 19.70
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00237.88± 21.48
OG003
Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00045.15± 27.62
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00249.56± 28.31
OG003
Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0)
Title
Measurements
OG00020.29± 25.04
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00217.65± 22.27
OG003
Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00039.15± 22.53
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00239.21± 27.05
OG003
Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG0000.41± 0.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.43± 0.50
OG003
Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG0006.75± 1.73
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0026.76± 1.40
OG003
Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0)
Title
Measurements
OG00032.94± 29.88
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.59± 32.94
OG003
Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG00032.34± 21.03
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00233.63± 24.25
OG003
Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00035.05± 16.56
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00233.62± 22.04
OG003
Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00034.78± 16.37
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00234.23± 20.63
OG003
Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00049.35± 24.69
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00254.92± 32.24
OG003
Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00015.16± 22.52
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00213.90± 19.39
OG003
Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00034.94± 20.00
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.66± 26.03
OG003
Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG0000.52± 0.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.53± 0.50
OG003
Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0)
Title
Measurements
OG0007.08± 1.41
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0027.05± 1.53
OG003
Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00029.18± 26.97
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00234.92± 32.71
OG003
Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG00028.82± 18.61
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00232.20± 21.52
OG003
Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG00032.17± 17.35
OG00143.67± 20.23
OG00230.68± 21.02
OG003
Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG00031.64± 16.38
OG00142.86± 19.06
OG00231.46± 19.54
OG003
Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG00057.00± 25.74
OG00139.50± 27.81
OG00258.41± 28.69
OG003
Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17
Title
Measurements
OG00014.00± 17.66
OG00120.00± 26.75
OG00212.73± 18.85
OG003
Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG00032.31± 19.05
OG00140.19± 21.76
OG00230.80± 24.04
OG003
Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17)
Title
Measurements
OG0000.53± 0.51
OG0010.50± 0.51
OG0020.55± 0.50
OG003
Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG0006.88± 1.44
OG0016.80± 1.40
OG0027.25± 1.31
OG003
Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17)
Title
Measurements
OG00026.50± 23.70
OG00138.00± 32.38
OG00235.00± 31.73
OG003
Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17)
Title
Measurements
OG00029.50± 19.33
OG00140.67± 20.85
OG00234.39± 25.39
OG003
CP-690,550 1 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00067
OG00120
OG00268
OG00313
OG00468
OG00573
OG00672
OG00779
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0)
Title
Measurements
OG000-0.95± 11.35
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-6.57± 15.20
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-3.43± 16.51
OG005-2.05± 14.11
OG006-7.45± 11.74
OG007-2.36± 17.85
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-4.29± 13.12
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0)
Title
Measurements
OG000-2.94± 10.26
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-7.76± 14.28
OG003
Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0)
Title
Measurements
OG000-3.68± 22.72
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.74± 21.04
OG003
Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-0.29± 19.70
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-5.29± 20.62
OG003
Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0)
Title
Measurements
OG000-5.64± 13.23
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-9.89± 17.97
OG003
Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0)
Title
Measurements
OG000-0.10± 0.52
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.01± 0.47
OG003
Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0)
Title
Measurements
OG000-0.13± 1.21
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.03± 1.07
OG003
Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0)
Title
Measurements
OG0003.28± 22.99
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.29± 22.26
OG003
Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0)
Title
Measurements
OG000-3.18± 18.47
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-5.00± 18.33
OG003
Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0)
Title
Measurements
OG000-5.54± 12.21
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-10.51± 20.72
OG003
Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0)
Title
Measurements
OG000-7.27± 11.71
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-11.21± 18.59
OG003
Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0)
Title
Measurements
OG0001.45± 22.39
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00211.19± 27.55
OG003
Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG000-3.87± 24.52
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-7.46± 24.89
OG003
Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG000-9.74± 16.98
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-13.43± 22.93
OG003
Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0)
Title
Measurements
OG0000.00± 0.54
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.07± 0.61
OG003
Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0)
Title
Measurements
OG0000.16± 1.43
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0020.40± 1.32
OG003
Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0)
Title
Measurements
OG0000.66± 22.20
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG002-0.34± 27.67
OG003
Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0)
Title
Measurements
OG000-6.56± 18.60
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00070
OG00121
OG00268
OG00313
OG00471
OG00573
OG00675
OG00779
OG00812
OG00969
OG01017
Title
Denominators
Categories
Baseline (n=70,0,68,0,71,73,75,79,0,69,0)
Title
Measurements
OG00028.17± 10.50
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00229.92± 11.98
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00428.76± 10.42
OG00530.06± 10.85
OG00629.48± 10.19
OG00729.76± 11.02
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00932.23± 11.13
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 2 (n=68,0,68,0,68,73,73,78,0,66,0)
Title
Measurements
OG00030.41± 12.01
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00232.65± 10.64
OG003
Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)
Title
Measurements
OG00033.25± 10.80
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00235.44± 11.16
OG003
Week 24 (n=39,20,44,13,55,64,59,51,12,35,17)
Title
Measurements
OG00036.69± 10.42
OG00128.08± 11.07
OG00235.48± 11.66
OG003
Participants who failed to achieve minimum improvement in CP-690,550 1 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG002
CP-690,550 3 mg
CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks.
OG003
CP-690,550 3 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 3 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG004
CP-690,550 5 mg
CP-690,550 5 mg tablet orally twice daily for 24 weeks.
OG005
CP-690,550 10 mg
CP-690,550 10 mg tablet orally twice daily for 24 weeks.
OG006
CP-690,550 15 mg
CP-690,550 15 mg tablet orally twice daily for 24 weeks.
OG007
CP-690,550 20 mg
CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks.
OG008
CP-690,550 20 mg to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in CP-690,550 20 mg treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
OG009
Placebo
Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks.
OG010
Placebo to CP-690,550 5 mg (R)
Participants who failed to achieve minimum improvement in placebo treatment arm, after Week 12 visit received CP-690,550 5 mg tablet orally twice daily up to Week 24.
Units
Counts
Participants
OG00068
OG00121
OG00268
OG00313
OG00468
OG00572
OG00673
OG00778
OG00812
OG00966
OG01017
Title
Denominators
Categories
Week 2 (n=68,0,68,0,68,72,73,78,0,66,0)
Title
Measurements
OG0001.96± 7.99
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0022.74± 7.80
OG003NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.54± 7.71
OG0052.80± 7.40
OG0063.68± 7.24
OG0073.37± 6.56
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.61± 6.21
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
Week 12 (n=61,0,59,0,63,65,64,69,0,61,0)
Title
Measurements
OG0004.82± 8.53
OG001NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0025.79± 10.95
OG003
Week 24 (n=39,20,44,13,55,64,59,50,12,35,17)
Title
Measurements
OG0006.23± 9.66
OG0013.73± 10.35
OG0025.33± 9.42
OG003
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0092 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0093 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0049 affected71 at risk
EG0051 affected74 at risk
EG0063 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0092 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0053 affected74 at risk
EG0062 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0102 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0053 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0043 affected71 at risk
EG0055 affected74 at risk
EG0064 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0043 affected71 at risk
EG0051 affected74 at risk
EG0062 affected75 at risk
EG0074 affected67 at risk
EG0080 affected13 at risk
EG0092 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0043 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0051 affected74 at risk
EG0062 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0054 affected74 at risk
EG0062 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0042 affected71 at risk
EG0055 affected74 at risk
EG0063 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0045 affected71 at risk
EG0052 affected74 at risk
EG0066 affected75 at risk
EG0074 affected67 at risk
EG0081 affected13 at risk
EG0093 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0062 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0072 affected67 at risk
EG0081 affected13 at risk
EG0092 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0053 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
3 affected
13 at risk
EG0045 affected71 at risk
EG0055 affected74 at risk
EG0062 affected75 at risk
EG0074 affected67 at risk
EG0082 affected13 at risk
EG0091 affected51 at risk
EG0102 affected18 at risk
2 affected
13 at risk
EG0045 affected71 at risk
EG0054 affected74 at risk
EG0065 affected75 at risk
EG0076 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0052 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0065 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0065 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0062 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0064 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
2 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0062 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0053 affected74 at risk
EG0061 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
1 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0042 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0101 affected18 at risk
1 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0041 affected71 at risk
EG0053 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
2 affected
13 at risk
EG0042 affected71 at risk
EG0053 affected74 at risk
EG0064 affected75 at risk
EG0079 affected67 at risk
EG0083 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0042 affected71 at risk
EG0052 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0043 affected71 at risk
EG0056 affected74 at risk
EG0062 affected75 at risk
EG0072 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
1 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0051 affected74 at risk
EG0060 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0081 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0042 affected71 at risk
EG0054 affected74 at risk
EG0062 affected75 at risk
EG0071 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0050 affected74 at risk
EG0061 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0100 affected18 at risk
0 affected
13 at risk
EG0041 affected71 at risk
EG0052 affected74 at risk
EG0062 affected75 at risk
EG0072 affected67 at risk
EG0080 affected13 at risk
EG0090 affected51 at risk
EG0101 affected18 at risk
0 affected
13 at risk
EG0040 affected71 at risk
EG0050 affected74 at risk
EG0060 affected75 at risk
EG0070 affected67 at risk
EG0080 affected13 at risk
EG0091 affected51 at risk
EG0100 affected18 at risk
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00446.48
OG00545.95
OG00654.67
OG00751.25
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00924.64
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00457.75
OG00555.41
OG00656.00
OG00750.00
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00937.68
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00454.93
OG00556.76
OG00664.00
OG00756.25
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00933.33
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
0.0
OG00453.5
OG00564.9
OG00662.7
OG00764.2
OG0080.0
OG00943.1
OG0100.0
0.0
OG00457.7
OG00562.2
OG00661.3
OG00764.2
OG0080.0
OG00947.1
OG0100.0
0.0
OG00459.2
OG00566.2
OG00665.3
OG00762.7
OG0080.0
OG00947.1
OG0100.0
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00411.27
OG00520.27
OG00626.67
OG00725.00
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.90
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00430.99
OG00527.03
OG00632.00
OG00727.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0098.70
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00432.39
OG00528.38
OG00641.33
OG00732.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00917.39
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00436.62
OG00528.38
OG00644.00
OG00736.25
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00917.39
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
0.0
OG00438.0
OG00536.5
OG00640.0
OG00741.8
OG0080.0
OG00921.6
OG0100.0
0.0
OG00438.0
OG00540.5
OG00648.0
OG00747.8
OG0080.0
OG00931.4
OG0100.0
0.0
OG00439.4
OG00539.2
OG00646.7
OG00746.3
OG0080.0
OG00931.4
OG0100.0
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.00
OG00514.86
OG00613.33
OG00712.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.45
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00416.90
OG0059.46
OG00616.00
OG00712.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.35
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00411.27
OG00516.22
OG00616.00
OG00717.50
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0095.80
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00418.31
OG00512.16
OG00624.00
OG00723.75
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0095.80
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
0.0
OG00418.3
OG00518.9
OG00624.0
OG00722.4
OG0080.0
OG0099.8
OG0100.0
0.0
OG00423.9
OG00524.3
OG00628.0
OG00728.4
OG0080.0
OG00913.7
OG0100.0
0.0
OG00421.1
OG00518.9
OG00632.0
OG00728.4
OG0080.0
OG0099.8
OG0100.0
7.29
± 2038.26
OG004341.52± 820.16
OG005170.23± 825.49
OG006-296.38± 1270.69
111.83
± 3626.48
OG004716.69± 1285.36
OG005402.21± 1428.69
OG006-453.18± 2265.12
239.54
± 5389.58
OG0041154.14± 1733.13
OG005725.67± 1954.96
OG006-571.99± 3310.17
588.45
± 8969.29
OG0041974.18± 3231.70
OG0051504.58± 2979.75
OG006-755.22± 5107.45
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00415.56± 10.44
OG00517.34± 12.13
OG00616.32± 13.18
OG00715.33± 12.59
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00918.86± 13.00
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00413.06± 11.59
OG00514.01± 14.73
OG00613.00± 12.48
OG00713.75± 13.08
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00916.17± 12.36
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00410.23± 10.44
OG00513.55± 14.38
OG00611.51± 12.67
OG00713.22± 13.25
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00914.74± 13.86
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0049.82± 11.08
OG00512.22± 13.75
OG0069.49± 11.71
OG00711.15± 13.76
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00913.57± 14.16
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00410.09± 11.65
OG00510.88± 12.79
OG00610.18± 12.65
OG00711.27± 13.68
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00913.77± 14.84
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
19.15
± 16.42
OG0048.64± 12.25
OG0059.77± 12.49
OG0068.39± 11.32
OG0077.07± 8.86
OG00826.25± 19.07
OG0098.51± 7.25
OG01015.56± 18.52
15.00
± 11.47
OG0047.16± 9.91
OG0058.27± 11.32
OG0066.98± 9.96
OG0076.51± 10.55
OG00823.00± 16.59
OG0097.62± 7.26
OG01015.24± 17.68
13.92
± 9.93
OG0046.85± 9.51
OG0058.20± 9.94
OG0066.37± 8.72
OG0075.87± 7.68
OG00821.67± 13.69
OG0095.33± 5.74
OG01015.88± 17.46
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-8.42± 9.73
OG005-10.77± 10.25
OG006-10.90± 11.13
OG007-9.59± 10.42
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-5.03± 10.05
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-11.01± 9.64
OG005-11.07± 9.94
OG006-12.14± 10.07
OG007-10.58± 9.60
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-6.69± 11.68
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-11.50± 9.06
OG005-11.93± 10.92
OG006-13.76± 11.73
OG007-12.26± 9.96
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-7.03± 13.26
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-10.88± 11.01
OG005-13.47± 9.96
OG006-14.24± 11.80
OG007-12.77± 10.92
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-6.84± 12.84
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-1.00
± 14.29
OG004-12.93± 12.63
OG005-14.58± 11.19
OG006-15.05± 11.31
OG007-15.65± 9.29
OG008-2.33± 15.69
OG009-10.16± 9.92
OG010-8.06± 10.88
-5.15
± 11.07
OG004-14.58± 11.94
OG005-16.08± 10.43
OG006-16.64± 10.73
OG007-15.67± 9.33
OG008-5.58± 11.32
OG009-11.05± 11.86
OG010-8.24± 11.19
-6.23
± 10.54
OG004-14.93± 11.72
OG005-16.36± 9.39
OG006-17.03± 10.39
OG007-16.36± 10.60
OG008-6.92± 12.62
OG009-13.17± 9.90
OG010-7.59± 12.39
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0049.51± 6.30
OG00510.14± 7.92
OG00610.07± 7.29
OG00710.14± 6.26
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00913.41± 9.47
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0048.01± 7.45
OG0057.53± 6.98
OG0067.85± 6.70
OG0078.61± 7.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00911.11± 8.58
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.22± 6.00
OG0057.10± 7.62
OG0066.60± 6.31
OG0077.66± 7.43
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00910.39± 9.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0045.35± 5.03
OG0056.78± 7.43
OG0066.01± 6.22
OG0077.22± 8.60
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0098.16± 8.02
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.13± 6.82
OG0055.50± 5.84
OG0064.85± 6.04
OG0076.80± 8.87
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0098.79± 9.10
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
10.00
± 10.51
OG0043.84± 4.40
OG0054.74± 5.64
OG0064.26± 5.40
OG0073.58± 3.54
OG00814.50± 12.99
OG0095.97± 5.98
OG0108.63± 7.70
8.54
± 9.85
OG0043.95± 5.80
OG0054.21± 5.59
OG0063.27± 4.02
OG0073.31± 4.19
OG00812.25± 8.25
OG0095.00± 6.65
OG0107.41± 9.27
7.00
± 7.14
OG0043.71± 4.33
OG0054.41± 6.86
OG0063.03± 3.75
OG0072.89± 2.97
OG00811.25± 9.81
OG0094.11± 3.90
OG0107.94± 8.90
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-5.97± 5.44
OG005-7.34± 6.27
OG006-7.64± 6.77
OG007-6.74± 8.13
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-4.56± 5.61
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-7.68± 6.30
OG005-7.68± 7.35
OG006-8.68± 6.73
OG007-7.97± 7.54
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-5.48± 6.91
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-8.74± 6.94
OG005-8.06± 7.40
OG006-9.31± 7.51
OG007-8.26± 8.30
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-7.15± 6.82
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-8.13± 8.00
OG005-9.20± 7.16
OG006-10.68± 7.37
OG007-8.84± 8.48
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-6.52± 8.28
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-2.46
± 5.77
OG004-10.60± 7.43
OG005-9.95± 6.97
OG006-10.66± 6.75
OG007-10.65± 7.09
OG008-5.83± 13.62
OG009-8.65± 6.58
OG010-6.88± 6.51
-3.92
± 5.72
OG004-10.39± 6.98
OG005-10.48± 7.21
OG006-11.61± 6.35
OG007-11.00± 6.99
OG008-8.08± 9.89
OG009-9.62± 7.31
OG010-7.88± 9.21
-5.46
± 6.77
OG004-10.25± 6.70
OG005-10.48± 6.33
OG006-11.70± 6.38
OG007-11.57± 7.50
OG008-9.08± 11.99
OG009-10.28± 7.46
OG010-7.35± 6.47
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00444.35± 24.31
OG00541.26± 22.18
OG00637.82± 22.17
OG00740.57± 27.24
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00946.91± 25.39
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00440.03± 24.25
OG00539.34± 25.09
OG00635.81± 23.88
OG00734.39± 24.29
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00942.02± 24.40
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00433.33± 24.18
OG00534.38± 23.15
OG00632.97± 23.50
OG00733.65± 25.47
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00942.21± 27.12
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00436.55± 25.00
OG00534.60± 24.04
OG00630.26± 22.20
OG00731.16± 24.86
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00941.34± 26.45
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00428.88± 22.80
OG00533.78± 25.50
OG00631.48± 24.86
OG00731.09± 26.57
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00941.02± 26.13
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
39.31
± 24.13
OG00428.98± 22.15
OG00530.33± 22.04
OG00627.07± 20.76
OG00724.56± 23.46
OG00851.25± 21.95
OG00930.08± 22.81
OG01038.38± 24.52
42.31
± 28.61
OG00425.91± 23.10
OG00533.66± 24.02
OG00624.69± 20.98
OG00724.58± 26.24
OG00843.92± 27.07
OG00925.08± 21.19
OG01033.00± 27.70
35.62
± 28.27
OG00424.45± 20.24
OG00528.65± 21.11
OG00624.47± 22.23
OG00719.92± 18.27
OG00835.33± 27.17
OG00927.14± 21.17
OG01033.65± 26.15
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-14.76± 24.06
OG005-17.80± 30.25
OG006-20.39± 28.95
OG007-24.74± 26.39
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-9.26± 28.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-21.07± 29.07
OG005-22.94± 29.71
OG006-22.61± 28.87
OG007-26.97± 26.15
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-8.61± 29.03
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-18.11± 29.71
OG005-21.84± 30.42
OG006-24.66± 30.16
OG007-29.08± 27.13
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-9.97± 28.48
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-25.75± 29.47
OG005-24.02± 27.96
OG006-23.95± 29.90
OG007-29.67± 28.25
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-10.30± 30.14
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-15.15
± 21.97
OG004-26.50± 28.81
OG005-26.64± 25.04
OG006-27.97± 29.32
OG007-32.09± 24.84
OG008-19.00± 29.73
OG009-17.22± 35.13
OG010-18.19± 21.36
-12.15
± 25.36
OG004-29.54± 30.99
OG005-22.78± 30.27
OG006-30.97± 31.28
OG007-32.95± 27.48
OG008-26.33± 33.15
OG009-22.22± 30.68
OG010-21.82± 21.49
-18.85
± 24.73
OG004-29.89± 30.87
OG005-28.51± 28.01
OG006-31.00± 31.88
OG007-36.98± 27.86
OG008-34.92± 31.74
OG009-21.08± 32.99
OG010-21.18± 26.30
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.56± 22.89
OG00542.32± 21.98
OG00635.73± 21.46
OG00741.80± 26.25
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00946.33± 25.02
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00438.94± 22.27
OG00538.53± 24.49
OG00634.76± 21.33
OG00737.47± 25.17
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00941.21± 24.46
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00433.01± 24.06
OG00535.41± 22.68
OG00630.56± 21.87
OG00734.86± 25.24
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00943.02± 25.14
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00436.50± 25.29
OG00536.09± 24.38
OG00630.61± 21.60
OG00731.85± 25.35
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00940.64± 25.32
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00429.66± 21.69
OG00535.05± 24.65
OG00632.53± 24.48
OG00730.76± 25.59
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.85± 25.75
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
39.31
± 27.48
OG00430.62± 22.56
OG00530.98± 22.06
OG00626.59± 20.19
OG00724.76± 22.53
OG00850.67± 23.10
OG00928.46± 22.69
OG01037.63± 23.11
42.08
± 27.48
OG00426.07± 22.75
OG00535.00± 23.51
OG00624.90± 20.57
OG00725.56± 23.20
OG00844.42± 27.38
OG00926.22± 21.09
OG01036.94± 27.13
38.23
± 27.28
OG00423.64± 21.82
OG00529.66± 21.58
OG00625.07± 23.20
OG00721.85± 18.07
OG00834.83± 27.04
OG00928.25± 21.49
OG01034.59± 27.87
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-15.70± 22.92
OG005-20.76± 26.76
OG006-21.82± 28.55
OG007-19.04± 29.28
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-10.65± 27.81
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-20.81± 24.06
OG005-24.03± 23.89
OG006-25.26± 30.85
OG007-22.99± 29.63
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-9.46± 23.90
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-17.44± 28.12
OG005-22.58± 25.37
OG006-24.81± 31.07
OG007-25.92± 30.55
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-11.48± 25.89
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-24.30± 24.57
OG005-24.77± 26.21
OG006-23.08± 30.87
OG007-28.09± 30.23
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-12.75± 28.20
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-22.00
± 26.01
OG004-24.05± 28.00
OG005-27.97± 24.02
OG006-28.90± 29.36
OG007-29.68± 31.20
OG008-13.67± 35.93
OG009-20.97± 31.57
OG010-14.81± 17.72
-19.23
± 28.78
OG004-28.33± 26.93
OG005-23.95± 27.82
OG006-31.12± 32.09
OG007-30.67± 31.38
OG008-19.92± 34.52
OG009-23.22± 27.31
OG010-13.53± 22.22
-23.08
± 31.06
OG004-29.84± 27.59
OG005-28.61± 25.31
OG006-30.83± 32.96
OG007-33.04± 32.02
OG008-29.50± 32.33
OG009-21.92± 27.51
OG010-15.88± 25.95
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.29± 20.12
OG00542.85± 19.42
OG00635.99± 15.97
OG00741.92± 22.30
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00949.05± 18.00
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00434.73± 17.40
OG00533.56± 19.77
OG00633.35± 19.24
OG00732.96± 22.38
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00940.23± 19.43
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00427.78± 18.40
OG00530.82± 19.95
OG00627.08± 17.28
OG00732.65± 23.41
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00937.85± 21.03
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00427.26± 19.97
OG00528.01± 19.90
OG00623.06± 17.18
OG00727.70± 21.09
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.66± 21.39
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00424.77± 18.80
OG00526.47± 19.69
OG00623.28± 17.89
OG00728.93± 23.44
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.70± 24.86
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
33.31
± 22.97
OG00423.67± 21.04
OG00523.00± 18.60
OG00619.31± 15.80
OG00718.60± 15.00
OG00848.42± 30.00
OG00926.22± 18.43
OG01027.44± 16.36
32.92
± 25.15
OG00420.65± 18.68
OG00524.05± 18.32
OG00616.19± 12.41
OG00718.84± 18.42
OG00844.67± 25.31
OG00921.95± 18.03
OG01033.94± 22.43
32.54
± 24.26
OG00416.91± 14.67
OG00521.25± 17.79
OG00614.68± 13.07
OG00714.49± 11.75
OG00841.00± 31.58
OG00920.67± 15.81
OG01032.18± 19.03
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-22.00± 20.79
OG005-27.67± 20.61
OG006-27.43± 21.04
OG007-25.31± 22.01
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-17.79± 18.95
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-28.80± 20.44
OG005-30.39± 20.61
OG006-33.26± 19.40
OG007-25.93± 23.04
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-20.15± 22.19
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-29.67± 24.30
OG005-33.63± 21.96
OG006-37.26± 19.37
OG007-30.66± 21.10
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-22.82± 22.89
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-31.58± 23.09
OG005-34.98± 20.53
OG006-36.80± 20.78
OG007-30.27± 22.44
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-21.77± 24.51
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-23.85
± 19.42
OG004-33.47± 26.06
OG005-38.45± 20.53
OG006-39.70± 20.34
OG007-38.65± 17.68
OG008-19.08± 29.20
OG009-29.89± 22.16
OG010-32.56± 15.65
-24.23
± 22.29
OG004-36.81± 24.26
OG005-37.41± 18.99
OG006-43.42± 16.85
OG007-38.16± 19.33
OG008-22.83± 26.51
OG009-34.16± 23.25
OG010-26.29± 24.43
-24.62
± 19.99
OG004-39.51± 22.83
OG005-40.61± 20.10
OG006-44.65± 16.76
OG007-41.91± 17.09
OG008-28.64± 31.29
OG009-35.06± 21.26
OG010-28.06± 20.84
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.20± 0.58
OG0051.16± 0.61
OG0061.15± 0.67
OG0071.23± 0.63
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.15± 0.64
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.13± 0.65
OG0051.08± 0.64
OG0061.12± 0.69
OG0071.14± 0.65
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.14± 0.66
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.03± 0.61
OG0051.02± 0.65
OG0061.05± 0.69
OG0071.05± 0.65
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.07± 0.70
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0041.06± 0.66
OG0050.89± 0.67
OG0060.98± 0.68
OG0070.98± 0.72
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.05± 0.71
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.94± 0.65
OG0050.95± 0.68
OG0060.96± 0.69
OG0070.90± 0.67
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.08± 0.74
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
1.18
± 0.77
OG0040.92± 0.60
OG0050.91± 0.68
OG0060.97± 0.75
OG0070.81± 0.67
OG0081.36± 0.67
OG0090.80± 0.64
OG0101.05± 0.80
1.13
± 0.78
OG0040.78± 0.57
OG0050.84± 0.65
OG0060.92± 0.72
OG0070.75± 0.63
OG0081.42± 0.62
OG0090.73± 0.65
OG0100.92± 0.75
1.05
± 0.84
OG0040.78± 0.62
OG0050.85± 0.66
OG0060.88± 0.69
OG0070.72± 0.61
OG0081.34± 0.78
OG0090.74± 0.66
OG0100.95± 0.68
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.32± 0.51
OG005-0.25± 0.45
OG006-0.31± 0.44
OG007-0.34± 0.50
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.05± 0.46
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.42± 0.54
OG005-0.32± 0.57
OG006-0.34± 0.47
OG007-0.42± 0.52
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.13± 0.59
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.40± 0.58
OG005-0.43± 0.66
OG006-0.39± 0.49
OG007-0.50± 0.61
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.12± 0.55
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.51± 0.61
OG005-0.37± 0.63
OG006-0.45± 0.50
OG007-0.58± 0.61
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.10± 0.57
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-0.08
± 0.31
OG004-0.52± 0.59
OG005-0.41± 0.63
OG006-0.45± 0.60
OG007-0.62± 0.62
OG008-0.46± 0.58
OG009-0.30± 0.52
OG010-0.01± 0.29
-0.13
± 0.41
OG004-0.64± 0.62
OG005-0.49± 0.58
OG006-0.51± 0.59
OG007-0.67± 0.65
OG008-0.41± 0.55
OG009-0.38± 0.54
OG010-0.11± 0.30
-0.21
± 0.32
OG004-0.61± 0.65
OG005-0.47± 0.62
OG006-0.53± 0.60
OG007-0.66± 0.72
OG008-0.48± 0.74
OG009-0.37± 0.54
OG010-0.08± 0.29
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.98± 10.05
OG0055.24± 9.59
OG0064.08± 4.79
OG0078.35± 13.48
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00918.10± 20.41
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0048.63± 12.54
OG0055.46± 9.76
OG0064.63± 8.68
OG0078.67± 13.62
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00915.30± 16.85
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0048.26± 14.30
OG0055.42± 10.04
OG0065.41± 8.63
OG00710.68± 17.49
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00915.18± 19.32
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0047.17± 11.47
OG00510.18± 24.04
OG0068.39± 11.39
OG0079.75± 18.92
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00920.38± 30.37
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.54± 9.68
OG0059.11± 20.08
OG0065.81± 7.25
OG0079.53± 15.08
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00919.69± 20.07
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
5.85
± 5.47
OG0045.40± 8.06
OG0056.77± 10.27
OG0069.79± 22.24
OG0076.52± 11.33
OG0086.89± 7.06
OG00913.08± 11.49
OG0106.52± 7.30
11.28
± 17.83
OG0047.93± 19.22
OG0055.58± 8.69
OG0063.46± 3.17
OG0074.75± 5.28
OG0087.89± 9.08
OG00916.14± 16.63
OG01012.10± 18.21
12.58
± 12.19
OG0045.92± 14.78
OG0056.66± 17.03
OG0066.51± 11.04
OG0074.54± 4.69
OG0087.19± 8.18
OG00913.39± 15.05
OG01016.21± 26.51
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-8.54± 16.65
OG005-9.45± 16.27
OG006-11.70± 17.89
OG007-6.69± 13.99
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-1.26± 12.51
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-9.81± 23.67
OG005-9.38± 16.02
OG006-10.73± 17.63
OG007-5.03± 17.94
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.51± 12.72
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-11.35± 21.25
OG005-4.97± 24.54
OG006-8.67± 18.05
OG007-6.11± 19.97
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.70± 25.55
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-12.52± 23.93
OG005-5.96± 23.26
OG006-10.18± 16.26
OG007-5.71± 20.18
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.07± 15.90
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-6.33
± 10.48
OG004-11.53± 22.00
OG005-8.18± 18.99
OG006-7.01± 27.54
OG007-8.16± 17.01
OG008-7.59± 12.45
OG009-2.59± 13.79
OG010-13.44± 12.75
-0.90
± 20.08
OG004-7.80± 23.28
OG005-9.60± 19.16
OG006-14.21± 16.73
OG007-9.65± 15.32
OG008-10.22± 13.83
OG0090.11± 15.15
OG010-7.52± 20.34
0.40
± 16.50
OG004-8.18± 19.26
OG005-8.72± 22.73
OG006-10.65± 18.76
OG007-8.75± 15.40
OG008-10.92± 15.78
OG009-2.16± 16.06
OG010-3.41± 26.61
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.26± 0.90
OG0054.18± 1.04
OG0064.18± 1.16
OG0074.28± 1.07
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.91± 1.07
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.03± 0.96
OG0053.66± 1.12
OG0063.75± 1.13
OG0073.99± 1.11
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.60± 1.01
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.68± 1.00
OG0053.59± 1.27
OG0063.60± 1.13
OG0073.94± 1.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.35± 1.04
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.54± 1.01
OG0053.61± 1.23
OG0063.38± 1.10
OG0073.72± 1.35
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.30± 1.08
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.57± 1.09
OG0053.40± 1.27
OG0063.28± 1.25
OG0073.61± 1.25
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0094.37± 1.29
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
4.19
± 1.48
OG0043.19± 1.10
OG0053.34± 1.22
OG0063.12± 1.25
OG0073.14± 1.06
OG0084.65± 1.08
OG0093.93± 1.06
OG0103.91± 1.19
4.24
± 1.56
OG0043.09± 1.17
OG0053.14± 1.29
OG0062.94± 1.04
OG0073.08± 1.11
OG0084.82± 1.24
OG0093.81± 1.23
OG0103.86± 1.24
4.08
± 1.35
OG0043.03± 1.05
OG0053.15± 1.19
OG0062.91± 1.12
OG0073.07± 0.98
OG0084.51± 1.61
OG0093.48± 1.06
OG0104.08± 1.37
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.09± 0.94
OG005-1.58± 1.09
OG006-1.71± 1.20
OG007-1.30± 1.06
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.57± 0.88
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.44± 0.99
OG005-1.66± 1.18
OG006-1.81± 1.17
OG007-1.38± 1.07
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.80± 0.93
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.56± 0.97
OG005-1.63± 1.25
OG006-2.02± 1.14
OG007-1.63± 1.17
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.83± 1.11
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.59± 1.18
OG005-1.82± 1.17
OG006-2.13± 1.32
OG007-1.72± 1.13
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.82± 1.11
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-0.81
± 1.20
OG004-1.93± 1.12
OG005-1.89± 1.13
OG006-2.31± 1.39
OG007-2.13± 1.04
OG008-0.88± 0.95
OG009-1.14± 1.03
OG010-1.43± 0.70
-0.76
± 1.22
OG004-2.05± 1.15
OG005-2.09± 1.28
OG006-2.49± 1.26
OG007-2.17± 0.96
OG008-0.95± 0.81
OG009-1.27± 1.37
OG010-1.47± 1.04
-0.92
± 1.17
OG004-2.06± 1.04
OG005-2.13± 1.12
OG006-2.49± 1.27
OG007-2.19± 1.04
OG008-1.26± 1.23
OG009-1.55± 1.25
OG010-1.25± 0.96
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.9
OG00546.4
OG00650.0
OG00741.9
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00923.0
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00447.6
OG00540.6
OG00633.8
OG00744.6
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00973.8
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00416.1
OG00528.1
OG00630.8
OG00721.4
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0098.2
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00448.4
OG00553.1
OG00649.2
OG00742.9
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.4
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00435.5
OG00518.8
OG00620.0
OG00734.3
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00957.4
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00431.8
OG00529.9
OG00631.8
OG00723.2
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00912.1
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.4
OG00550.7
OG00650.0
OG00744.9
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00943.1
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00425.8
OG00519.4
OG00618.2
OG00731.9
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00944.8
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00437.1
OG00532.3
OG00643.3
OG00737.3
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00913.8
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00446.8
OG00545.2
OG00647.8
OG00740.3
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00946.6
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00416.1
OG00522.6
OG0069.0
OG00722.4
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.7
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00433.3
OG00541.3
OG00651.6
OG00736.9
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00916.7
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00450.0
OG00539.7
OG00637.1
OG00744.6
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00936.7
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00416.7
OG00519.0
OG00611.3
OG00718.5
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00946.7
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
30.8
OG00451.9
OG00550.0
OG00648.3
OG00752.7
OG00811.1
OG00927.0
OG01018.8
23.1
OG00437.0
OG00534.4
OG00643.1
OG00743.6
OG00833.3
OG00940.5
OG01062.5
46.2
OG00411.1
OG00515.6
OG0068.6
OG0073.6
OG00855.6
OG00932.4
OG01018.8
15.4
OG00461.4
OG00552.4
OG00657.9
OG00752.7
OG0080.0
OG00930.6
OG01029.4
46.2
OG00428.1
OG00536.5
OG00635.1
OG00740.0
OG00858.3
OG00936.1
OG01047.1
38.5
OG00410.5
OG00511.1
OG0067.0
OG0077.3
OG00841.7
OG00933.3
OG01023.5
23.1
OG00452.8
OG00558.7
OG00666.1
OG00759.6
OG00825.0
OG00933.3
OG01023.5
38.5
OG00437.7
OG00530.2
OG00623.2
OG00734.6
OG00833.3
OG00941.7
OG01047.1
38.5
OG0049.4
OG00511.1
OG00610.7
OG0075.8
OG00841.7
OG00925.0
OG01029.4
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0048.06
OG00519.05
OG00616.92
OG00710.00
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.28
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00413.64
OG00524.24
OG00622.73
OG00710.14
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.45
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00419.35
OG00521.31
OG00623.88
OG00720.90
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0096.90
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00416.67
OG00532.26
OG00637.10
OG00724.62
OG008NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0096.67
OG010NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
23.1
OG00424.1
OG00530.2
OG00637.9
OG00729.1
OG00811.1
OG0098.1
OG01012.5
15.4
OG00435.1
OG00537.1
OG00638.6
OG00730.9
OG0080.0
OG00913.9
OG01017.6
15.4
OG00441.5
OG00536.5
OG00639.3
OG00732.7
OG00816.7
OG00919.4
OG01017.6
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00435.54± 8.69
OG00534.64± 10.72
OG00633.70± 9.85
OG00733.13± 9.32
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00937.23± 9.51
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00435.36± 8.23
OG00535.11± 7.85
OG00634.98± 8.19
OG00734.20± 8.18
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.93± 8.71
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00435.12± 8.90
OG00536.52± 9.28
OG00635.94± 8.44
OG00736.08± 8.48
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00936.50± 9.38
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00441.54± 9.39
OG00542.60± 10.83
OG00640.81± 11.75
OG00740.97± 9.98
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00944.08± 11.63
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00437.72± 10.38
OG00538.99± 10.80
OG00638.01± 11.06
OG00738.03± 10.70
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00940.09± 11.08
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00437.21± 12.51
OG00536.23± 12.64
OG00634.73± 14.42
OG00735.13± 13.45
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.37± 13.94
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00441.88± 12.02
OG00542.79± 10.99
OG00639.68± 12.65
OG00739.91± 12.53
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00942.91± 13.08
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00432.99± 8.03
OG00532.96± 8.15
OG00633.19± 7.31
OG00732.11± 8.57
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.41± 8.59
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.81± 11.80
OG00543.53± 11.00
OG00640.92± 13.00
OG00741.68± 12.17
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00944.72± 13.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00436.45± 9.78
OG00536.25± 10.75
OG00637.80± 10.76
OG00737.49± 11.48
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00936.23± 11.37
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00438.26± 10.21
OG00539.71± 9.69
OG00639.41± 10.03
OG00740.17± 10.41
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.79± 10.14
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.73± 9.57
OG00544.00± 10.81
OG00644.39± 9.40
OG00744.21± 9.78
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.46± 10.15
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00440.11± 9.54
OG00539.15± 8.76
OG00640.05± 9.44
OG00741.10± 9.78
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00939.54± 10.42
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00446.33± 10.59
OG00545.99± 10.68
OG00647.82± 10.24
OG00746.03± 11.42
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00946.48± 12.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.28± 10.82
OG00542.84± 10.06
OG00643.93± 9.81
OG00744.23± 10.53
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00941.38± 10.87
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00439.90± 12.87
OG00539.01± 12.07
OG00639.07± 11.96
OG00741.33± 13.30
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00940.39± 12.49
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00445.34± 13.08
OG00543.08± 9.84
OG00645.24± 10.70
OG00746.11± 11.49
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00943.36± 12.67
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00438.27± 9.31
OG00539.52± 9.30
OG00639.97± 8.98
OG00739.64± 10.20
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00937.89± 9.94
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00445.84± 13.41
OG00544.18± 10.26
OG00645.61± 10.59
OG00746.65± 11.64
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00945.08± 12.48
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
39.39
± 11.83
OG00440.04± 10.81
OG00538.19± 10.88
OG00638.62± 11.08
OG00740.51± 12.11
OG00832.31± 11.36
OG00939.44± 10.64
OG01038.09± 10.04
38.96
± 10.26
OG00441.09± 9.12
OG00540.32± 10.91
OG00640.69± 9.67
OG00741.97± 10.80
OG00835.02± 10.72
OG00944.27± 9.80
OG01042.45± 9.44
43.07
± 9.91
OG00444.96± 9.23
OG00544.52± 10.98
OG00645.76± 9.67
OG00746.89± 10.25
OG00840.32± 11.00
OG00943.11± 9.54
OG01044.24± 8.09
37.35
± 5.95
OG00441.35± 10.23
OG00541.09± 9.27
OG00641.40± 9.24
OG00744.03± 9.52
OG00835.81± 11.52
OG00943.16± 9.70
OG01040.68± 8.34
47.29
± 6.58
OG00448.40± 10.41
OG00547.55± 10.18
OG00650.11± 11.68
OG00750.50± 10.98
OG00841.94± 13.65
OG00949.75± 11.83
OG01048.23± 11.92
43.84
± 9.05
OG00445.25± 11.64
OG00543.56± 10.73
OG00644.67± 10.31
OG00746.35± 10.53
OG00838.67± 12.38
OG00945.18± 10.60
OG01043.05± 10.04
37.94
± 12.35
OG00441.46± 12.40
OG00540.15± 11.58
OG00640.39± 11.88
OG00742.31± 13.71
OG00837.09± 16.56
OG00942.27± 13.09
OG01046.28± 9.13
44.59
± 7.04
OG00447.29± 13.62
OG00543.89± 10.93
OG00646.86± 11.73
OG00747.24± 11.36
OG00843.44± 12.84
OG00945.63± 14.22
OG01047.52± 11.26
39.74
± 9.76
OG00441.12± 9.22
OG00540.85± 9.79
OG00640.99± 9.14
OG00742.81± 10.22
OG00834.40± 10.57
OG00942.09± 9.20
OG01039.41± 9.58
44.52
± 7.18
OG00447.34± 13.41
OG00545.03± 11.20
OG00647.21± 11.71
OG00748.03± 11.81
OG00843.35± 13.89
OG00947.08± 15.31
OG01049.27± 9.52
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0042.68± 9.44
OG0054.52± 11.62
OG0065.20± 9.27
OG0076.86± 9.69
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.01± 9.91
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0047.28± 10.29
OG0058.74± 10.66
OG0069.23± 9.48
OG00710.54± 9.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.23± 8.98
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.78± 8.81
OG0052.73± 7.46
OG0064.32± 8.59
OG0074.97± 9.64
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.47± 10.32
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.68± 9.86
OG0052.29± 8.80
OG0066.87± 8.76
OG0075.22± 8.28
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.45± 11.66
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.26± 9.93
OG0053.49± 11.84
OG0064.70± 10.33
OG0075.84± 12.43
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.80± 9.70
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0042.25± 11.23
OG0052.73± 13.28
OG0063.77± 13.04
OG0075.33± 12.06
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.96± 12.04
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.43± 10.19
OG0050.04± 9.08
OG0064.68± 8.73
OG0075.59± 9.87
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.88± 9.76
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0045.30± 8.03
OG0056.32± 8.72
OG0066.77± 7.29
OG0077.98± 7.95
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.71± 7.43
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0042.72± 9.57
OG0050.28± 10.13
OG0063.81± 9.58
OG0074.18± 10.04
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-1.40± 9.18
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
4.37
± 8.35
OG0047.77± 9.41
OG0056.41± 11.62
OG0066.63± 10.30
OG0078.81± 10.48
OG0086.49± 8.15
OG0093.74± 9.56
OG0104.21± 9.84
4.52
± 6.77
OG0046.01± 10.23
OG0055.56± 9.76
OG0066.61± 9.33
OG0077.25± 11.27
OG0085.51± 10.50
OG0095.85± 11.43
OG0104.75± 8.64
9.75
± 7.27
OG00410.09± 10.44
OG0059.21± 10.31
OG00610.44± 10.51
OG00711.86± 10.67
OG00810.67± 12.01
OG0095.92± 10.51
OG0107.73± 7.63
4.11
± 9.07
OG0046.34± 7.85
OG0054.68± 8.77
OG0065.41± 7.88
OG0076.43± 8.93
OG0085.92± 9.84
OG0094.20± 12.05
OG0104.04± 3.82
5.04
± 10.16
OG0046.64± 9.03
OG0053.52± 9.27
OG0068.53± 9.99
OG0077.95± 11.17
OG0086.76± 11.52
OG0092.08± 13.86
OG0106.06± 6.19
5.87
± 10.31
OG0047.54± 10.36
OG0054.16± 11.99
OG0064.91± 10.27
OG0076.79± 11.86
OG0083.64± 11.71
OG0093.33± 12.73
OG0103.85± 9.20
-0.30
± 13.69
OG0044.24± 11.81
OG0054.01± 13.30
OG0065.18± 11.73
OG0075.57± 14.61
OG0082.27± 16.86
OG0090.97± 13.70
OG0102.29± 11.17
4.98
± 11.27
OG0045.43± 11.92
OG0050.36± 10.48
OG0065.44± 8.23
OG0075.31± 12.73
OG0086.57± 12.84
OG0090.70± 9.97
OG0100.99± 10.10
6.62
± 5.93
OG0048.31± 8.48
OG0057.99± 9.21
OG0067.81± 8.84
OG0079.59± 8.67
OG0087.83± 7.89
OG0096.26± 9.97
OG0106.40± 8.08
2.48
± 11.80
OG0044.46± 10.55
OG0050.73± 10.85
OG0064.78± 9.04
OG0074.52± 12.52
OG0083.44± 14.10
OG009-0.07± 12.42
OG0101.57± 8.22
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.62± 0.26
OG0050.65± 0.23
OG0060.63± 0.27
OG0070.64± 0.25
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.55± 0.31
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
0.64
± 0.25
OG0040.70± 0.23
OG0050.68± 0.23
OG0060.65± 0.25
OG0070.71± 0.27
OG0080.56± 0.32
OG0090.65± 0.22
OG0100.58± 0.32
0.23
± 0.37
OG0040.19± 0.30
OG0050.20± 0.31
OG0060.18± 0.29
OG0070.17± 0.32
OG0080.20± 0.45
OG0090.13± 0.30
OG0100.03± 0.29
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00440.22± 19.00
OG00539.05± 18.56
OG00642.87± 20.62
OG00740.49± 21.33
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00938.86± 19.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00446.20± 27.95
OG00550.27± 26.84
OG00649.19± 28.13
OG00751.00± 30.55
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00951.45± 28.45
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00417.75± 22.82
OG00517.30± 22.29
OG00621.87± 25.93
OG00720.50± 27.55
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00922.61± 25.88
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00442.61± 25.40
OG00541.17± 25.36
OG00648.37± 25.66
OG00744.42± 27.37
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00940.34± 26.04
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.46± 0.50
OG0050.45± 0.50
OG0060.47± 0.50
OG0070.50± 0.50
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.52± 0.50
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0047.32± 7.65
OG0057.28± 3.54
OG0066.64± 1.61
OG0076.90± 1.52
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0096.71± 1.47
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00444.51± 33.16
OG00539.73± 33.19
OG00636.00± 34.01
OG00735.25± 32.49
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.94± 33.88
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00432.86± 19.17
OG00534.50± 19.03
OG00635.91± 22.08
OG00735.04± 22.93
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00933.04± 20.69
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00434.22± 21.10
OG00535.25± 19.10
OG00632.97± 21.75
OG00735.78± 20.40
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.34± 20.21
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00434.74± 20.11
OG00535.65± 19.37
OG00635.27± 20.56
OG00736.22± 19.65
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.67± 18.79
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00453.24± 31.64
OG00553.42± 25.40
OG00657.53± 28.81
OG00750.51± 27.68
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00954.24± 29.87
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00417.94± 22.70
OG00522.74± 24.11
OG00615.34± 21.74
OG00720.25± 26.11
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00917.88± 23.57
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00435.00± 23.80
OG00534.93± 24.83
OG00638.73± 26.23
OG00735.87± 24.33
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00937.33± 25.29
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.53± 0.50
OG0050.52± 0.50
OG0060.52± 0.50
OG0070.44± 0.50
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.59± 0.50
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.72± 1.26
OG0057.05± 1.30
OG0067.10± 1.70
OG0076.78± 1.65
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0097.08± 1.53
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00437.01± 31.38
OG00535.62± 33.21
OG00630.96± 33.01
OG00730.63± 30.18
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.76± 35.17
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00431.08± 21.66
OG00533.79± 20.97
OG00632.69± 21.26
OG00731.73± 22.32
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00930.51± 20.56
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00433.39± 20.64
OG00534.92± 18.85
OG00635.00± 19.41
OG00732.81± 21.22
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.26± 22.07
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00433.61± 19.83
OG00535.26± 19.48
OG00636.33± 19.86
OG00733.44± 21.57
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00934.50± 20.96
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00453.17± 29.99
OG00554.00± 26.74
OG00656.09± 28.21
OG00758.43± 27.59
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00954.59± 27.72
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00420.32± 27.24
OG00520.00± 23.72
OG00618.75± 22.50
OG00721.43± 26.00
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00920.98± 28.85
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00432.52± 23.96
OG00534.27± 25.00
OG00639.16± 25.16
OG00734.18± 27.10
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.41± 26.22
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.48± 0.50
OG0050.54± 0.50
OG0060.45± 0.50
OG0070.51± 0.50
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.48± 0.50
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.71± 1.49
OG0056.85± 1.33
OG0066.98± 1.74
OG0077.60± 5.37
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0098.10± 9.47
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00441.59± 32.19
OG00535.69± 32.11
OG00634.69± 32.71
OG00733.43± 29.63
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00930.82± 31.53
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00431.01± 23.10
OG00534.36± 23.22
OG00632.29± 20.62
OG00730.57± 25.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00928.96± 18.77
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
38.21
± 17.46
OG00432.55± 22.35
OG00532.50± 18.22
OG00629.89± 18.91
OG00725.45± 17.75
OG00844.44± 27.09
OG00929.51± 19.04
OG01032.55± 22.31
38.80
± 18.07
OG00432.18± 21.24
OG00532.95± 18.88
OG00631.18± 19.77
OG00726.76± 17.75
OG00847.27± 27.08
OG00930.41± 18.52
OG01033.04± 21.93
46.15
± 18.05
OG00455.64± 31.61
OG00557.34± 26.32
OG00657.46± 26.43
OG00766.92± 28.60
OG00844.17± 34.50
OG00957.65± 27.64
OG01055.29± 33.56
18.46
± 17.25
OG00414.18± 20.61
OG00517.19± 23.33
OG00611.53± 19.72
OG00711.15± 18.33
OG00825.00± 32.05
OG00913.53± 15.35
OG01014.12± 25.26
38.08
± 28.62
OG00432.77± 25.76
OG00532.73± 26.78
OG00632.61± 26.23
OG00728.49± 23.70
OG00852.19± 29.21
OG00930.33± 24.00
OG01036.40± 27.29
0.38
± 0.51
OG0040.45± 0.50
OG0050.55± 0.50
OG0060.45± 0.50
OG0070.57± 0.50
OG0080.33± 0.49
OG0090.58± 0.50
OG0100.41± 0.51
6.69
± 1.65
OG0047.93± 7.26
OG0056.94± 1.23
OG0067.05± 1.85
OG0077.12± 1.20
OG0089.42± 12.87
OG0097.43± 1.09
OG0106.41± 1.42
44.62
± 32.82
OG00437.41± 32.05
OG00538.13± 33.37
OG00635.25± 30.25
OG00738.46± 32.62
OG00835.00± 28.44
OG00927.06± 32.62
OG01034.12± 33.74
31.79
± 18.49
OG00429.94± 20.68
OG00532.40± 24.05
OG00628.70± 19.93
OG00726.03± 21.42
OG00833.89± 25.34
OG00927.06± 17.67
OG01023.14± 18.12
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-4.93± 14.92
OG005-3.75± 12.36
OG006-7.06± 10.93
OG007-4.07± 15.98
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-3.30± 12.13
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0046.76± 25.06
OG0053.70± 26.11
OG0067.64± 16.74
OG007-0.51± 28.68
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0093.18± 19.70
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.29± 25.27
OG0055.48± 21.15
OG006-6.03± 21.78
OG0070.00± 20.51
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-5.76± 25.24
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-6.82± 18.04
OG005-6.73± 15.61
OG006-8.77± 15.11
OG007-7.85± 20.80
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.81± 17.05
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.04± 0.44
OG0050.07± 0.56
OG0060.04± 0.54
OG007-0.05± 0.53
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.08± 0.36
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.69± 7.75
OG005-0.21± 3.75
OG0060.41± 1.21
OG007-0.09± 1.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.36± 0.99
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-7.46± 21.97
OG005-4.66± 23.46
OG006-4.11± 21.33
OG007-4.05± 23.62
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.91± 23.91
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.37± 18.05
OG005-0.73± 16.20
OG006-2.74± 15.79
OG007-3.03± 17.76
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.22± 18.47
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-3.97± 18.57
OG005-2.00± 19.98
OG006-5.19± 19.19
OG007-4.62± 17.24
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.95± 18.20
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-5.59± 18.71
OG005-3.64± 18.32
OG006-5.63± 17.18
OG007-6.42± 15.31
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-3.03± 17.70
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0045.87± 27.51
OG0054.77± 29.32
OG0066.51± 25.15
OG0076.57± 32.16
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0090.82± 23.47
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0043.81± 28.70
OG0052.46± 26.10
OG006-2.81± 23.87
OG0071.43± 24.15
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-1.97± 25.22
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-9.25± 23.07
OG005-6.73± 22.54
OG006-8.22± 20.59
OG007-8.45± 18.59
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-2.97± 21.46
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0040.03± 0.64
OG0050.08± 0.62
OG006-0.05± 0.57
OG0070.01± 0.58
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-0.08± 0.53
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-0.73± 8.24
OG005-0.42± 3.80
OG0060.28± 1.52
OG0070.74± 5.57
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0091.33± 9.25
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-2.54± 28.85
OG005-2.15± 26.25
OG0061.56± 24.25
OG007-1.14± 22.04
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-3.28± 19.38
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG004-1.06± 19.20
OG0051.54± 23.06
OG006-2.81± 20.33
OG007-4.90± 20.72
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG009-4.37± 21.56
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
-6.92
± 18.13
OG004-4.12± 20.03
OG005-3.33± 16.38
OG006-8.62± 18.34
OG007-7.82± 18.23
OG008-3.33± 20.84
OG009-6.27± 19.96
OG010-2.16± 16.71
-8.50
± 16.00
OG004-6.04± 19.83
OG005-4.83± 16.17
OG006-9.82± 16.06
OG007-9.24± 18.00
OG008-3.38± 18.83
OG009-6.01± 18.67
OG010-1.96± 18.70
9.23
± 23.97
OG0048.00± 28.11
OG0056.72± 29.33
OG0065.52± 26.70
OG00711.92± 32.36
OG008-1.67± 39.73
OG009-1.18± 29.72
OG0108.82± 19.00
-1.54
± 26.41
OG004-3.27± 24.27
OG0050.63± 24.94
OG006-10.17± 25.56
OG007-5.38± 19.45
OG008-6.67± 21.46
OG009-11.18± 21.57
OG0103.53± 26.68
-13.75
± 21.22
OG004-6.59± 25.51
OG005-6.64± 22.53
OG006-13.98± 18.70
OG007-8.94± 22.39
OG008-7.19± 18.41
OG009-7.06± 23.78
OG010-1.18± 27.63
-0.08
± 0.64
OG0040.02± 0.62
OG0050.08± 0.65
OG006-0.05± 0.53
OG0070.02± 0.54
OG0080.00± 0.74
OG009-0.08± 0.60
OG010-0.06± 0.56
0.38
± 1.66
OG0040.33± 2.13
OG005-0.42± 3.97
OG0060.31± 1.44
OG0070.08± 1.04
OG0083.36± 13.89
OG0090.29± 1.45
OG0100.24± 1.25
6.15
± 18.95
OG004-7.04± 24.92
OG0050.31± 28.84
OG0062.37± 22.92
OG0071.54± 28.79
OG0085.00± 30.90
OG009-6.47± 26.84
OG010-1.18± 11.11
-4.10
± 15.04
OG004-2.18± 21.08
OG005-1.04± 20.03
OG006-6.55± 20.02
OG007-6.80± 21.19
OG008-4.24± 18.68
OG009-7.06± 17.36
OG010-2.35± 15.45
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00432.46± 11.78
OG00532.51± 10.58
OG00633.41± 10.10
OG00733.36± 10.93
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00933.88± 8.90
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00434.30± 10.87
OG00533.17± 9.43
OG00635.05± 10.17
OG00733.99± 11.61
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG00935.42± 10.04
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
34.92
± 9.40
OG00436.78± 10.75
OG00535.36± 10.01
OG00636.80± 9.85
OG00738.24± 9.46
OG00829.50± 12.27
OG00937.17± 10.12
OG01037.47± 9.87
NA
± NA
Data not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0044.90± 8.98
OG0052.18± 9.25
OG0065.41± 9.02
OG0074.51± 9.27
OG008NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.
OG0092.71± 9.94
OG010NA± NAData not available at this time point since the reassignment to CP-690,550 5 mg was after Week 12.